Skip to main content
    P

    PolyPid (PYPD)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.90
    +0.07 (+1.45%)

    Market Cap: $98.11M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    65%(17/26)
    Avg Surprise
    -99.06%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$0.27
    Range$-0.41 - $0.96
    4 analysts
    EPS RevisionsNo revisions (7d)
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.32+185.7%
    60d ago$0.30-11.5%
    30d ago$0.270.0%
    7d ago$0.270.0%
    Current$0.27
    Revenue Consensus
    $15M
    Range$0 - $30M
    4 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.35
    Range$-1.14 - $0.50
    4 analysts
    Revenue Consensus
    $0
    Range$-15000000 - $15M
    4 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.35---
    Sep 26EST
    		-$0.27---
    Jun 26
    Reported Aug 12
    		$-0.35$-0.34-2.94%Miss+55.1%
    Mar 26
    Reported May 13
    		$-0.35$-0.43+18.60%Beat+50.0%
    Dec 25
    Reported Feb 11
    		$-0.41$-0.33-24.24%Miss+61.7%
    Sep 25
    Reported Nov 12
    		$-0.37$-0.52+28.85%Beat+69.7%
    Jun 25
    Reported Aug 13
    		$-0.78$-0.55-41.82%Miss+37.6%
    Mar 25
    Reported May 14
    		$-0.70$-0.82+14.63%Beat+48.9%
    Dec 24
    Reported Feb 12
    		$-1.07$-0.88-21.59%Miss+72.1%
    Sep 24
    Reported Nov 13
    		$-1.22$-1.00-22.00%Miss+64.1%
    Jun 24
    Reported Aug 14
    		$-1.25$-1.30+3.85%Beat+88.4%
    Mar 24
    Reported May 8
    		$-1.37$-1.41+2.84%Beat+83.7%
    Dec 23
    Reported Feb 14
    		$-3.84$-4.29+10.49%Beat+60.0%
    Sep 23
    Reported Nov 8
    		$-3.40$-4.43+23.25%Beat+76.4%
    Jun 23
    Reported Aug 9
    		$-10.80$-13.32+18.92%Beat+41.0%
    Mar 23
    Reported May 10
    		$-8.40$-4.80-75.00%Miss+55.6%
    Dec 22
    Reported Feb 8
    		$-9.60$-12.36+22.33%Beat+54.9%
    Sep 22
    Reported Nov 9
    		$-14.40$-16.22+11.22%Beat+9.4%
    Jun 22
    Reported Aug 10
    		$-18.30$-20.10+8.96%Beat-8.9%
    Mar 22
    Reported May 11
    		$-18.90$-18.92+0.11%Beat-34.0%
    Dec 21
    Reported Feb 9
    		$-21.30$-16.64-28.00%Miss-73.2%
    Sep 21
    Reported Nov 10
    		$-15.90$-18.83+15.56%Beat-51.4%
    Jun 21
    Reported Aug 11
    		$-16.80$-15.75-6.67%Miss+91.2%
    Mar 21
    Reported May 12
    		$-14.10$-15.00+6.00%Beat-4238.5%
    Dec 20
    Reported Feb 10
    		$-12.30$-15.23+19.24%Beat-280.8%
    Sep 20
    Reported Nov 11
    		$-10.50$-12.20+13.93%Beat-1120.9%
    Jun 20
    Reported Aug 19
    		$-191.10$-6.90-2669.57%Miss-
    Mar 20
    Reported Jun 29
    		$-0.33N/A+97.42%Beat-
    Dec 17
    Reported Mar 14
    		$-3.23$0.00N/AMiss-
    Sep 17
    Reported Dec 20
    		$-0.86$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-3.31EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-243.60%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio1.35xQuick Ratio1.14x
    Trading Statistics
    Beta1.38Avg Volume88.35K
    52-Week High$5.7352-Week Low$3.10

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$5.01
    SMA 20$5.15
    SMA 50$5.09
    SMA 200$4.68
    EMA 10$5.00
    EMA 20$5.07
    EMA 50$5.05
    EMA 200$4.63

    MACD

    Line: -0.06Signal: -0.01Hist: -0.05

    ADX

    ADX: 19.8+DI: 12.7-DI: 23.4

    Aroon & PSAR

    Aroon Up64.0
    Aroon Down100.0
    PSAR$5.23

    Bollinger Bands

    Upper Band$5.51
    Lower Band$4.78
    %B Position1418%(Upper)
    Band Width0.16

    RSI (14-Day)

    Neutral
    42.9

    Momentum Oscillators

    Stoch %K17.7
    Stoch %D22.6
    Williams %R-73.0
    ROC (10d)-8.8%
    Momentum-0.47
    CCI (20d)-137.5
    MFI (14d)19.5

    Volatility Measures

    ATR (14d)$0.25(5.1%)
    StdDev (20d)0.18
    Hist Vol40.0%(Moderate)

    Volume Flow

    VWAP$4.84
    OBV24.0M
    AD Line-17.3M
    CMF (20d)-0.033

    Volume Metrics

    Avg Vol (20d)88.1K
    Vol Ratio1.4x
    VWMA (20d)$5.13

    Pivot Points

    R3$5.14
    R2$5.04
    R1$4.94
    Pivot Point$4.84
    S1$4.74
    S2$4.64
    S3$4.54

    Advanced Oscillators

    TSI-8.34
    Ultimate Osc46.3
    KST-19.17

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$0$0$0$0$0$0
    Cost of RevenueN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
    Gross ProfitN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
    Operating Expenses$-7,849,000$7.76M$-8,530,000$7.46M$9.40M$7.58M$8.22M$7.39M$6.12M$6.30M$6.00M$5.26M
    R&D$6.13M$5.76M$6.22M$5.26M$6.21M$6.12M$7.03M$5.97M$4.76M$5.05M$4.59M$3.81M
    SG&A$1.26M$1.59M$1.76M$1.77M$2.49M$1.17M$996,000$1.17M$1.10M$1.01M$1.22M$1.19M
    Operating Income$7.85M$-7,760,000$8.53M$-7,455,000$-9,403,000$-7,579,000$-8,221,000$-7,386,000$-6,121,000$-6,301,000$-5,999,000$-5,260,000
    Interest Income$6,000$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$15.69M$0$24,000$0$521,000$678,000$286,000$354,000$171,000$140,000$348,000$319,000
    Income Before Tax$-7,843,000$-7,728,000$-8,554,000$-7,429,000$-9,924,000$-8,257,000$-8,507,000$-7,740,000$-6,292,000$-6,441,000$-6,347,000$-5,579,000
    Income Tax Expense$6,000$0$-81,000$22,000$53,000$11,000$13,000$20,000$2,000$7,000$9,000$25,000
    Net Income$-7,849,000$-7,728,000$-8,473,000$-7,451,000$-9,977,000$-8,268,000$-8,520,000$-7,760,000$-6,294,000$-6,448,000$-6,356,000$-5,604,000
    EBITDA$-7,464,000$-7,728,000$-7,072,000$-7,429,000$-9,403,000$-7,579,000$-8,221,000$-7,386,000$-6,121,000$-6,301,000$-5,999,000$-5,260,000
    EBIT$-7,849,000$-7,760,000$-8,530,000$-7,455,000$-9,403,000$-7,579,000$-8,221,000$-7,386,000$-6,344,276$-6,301,000$-6,042,812$-5,220,414
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about PYPD

    News

    PolyPid to Host Virtual Investor Day on Wednesday, October 28, 2026

    PolyPid Ltd. announced it will host a virtual Investor Day on October 28, 2026, to present its "PolyPid 2030" long-term growth and pipeline strategy. The event will include updates on its lead product candidate...

    GlobeNewswire•10/15/26•Bullish

    What PolyPid’s Bold Moves in Europe Could Mean for D-PLEX₁₀₀’s Global Potential (NASDAQ: PYPD)

    PolyPid recently announced two significant developments in Europe regarding its lead product, D-PLEX₁₀₀: the European Medicines Agency validated its Marketing Authorization Application and the company regained full...

    The Globe and Mail•10/10/26•Bullish

    PolyPid Ltd. (PYPD) Gets EMA MAA Validation, Reclaims EU Rights for D-PLEX100

    PolyPid Ltd. (PYPD) has announced that the European Medicines Agency (EMA) validated its Marketing Authorization Application (MAA) for D-PLEX100...

    TradingView•10/9/26•Bullish

    What PolyPid's Bold Moves in Europe Could Mean for D-PLEX₁₀₀'s Global Potential (NASDAQ: PYPD)

    PolyPid recently announced two significant developments in Europe for its product D-PLEX₁₀₀: the European Medicines Agency validated its Marketing Authorization Application and PolyPid regained full European...

    Benzinga•10/9/26•Bullish

    PolyPid Ltd. (PYPD) EMA Validates D-PLEX100 MAA; Company Reclaims EU Rights

    PolyPid Ltd. announced that the European Medicines Agency (EMA) validated its Marketing Authorization Application (MAA) for D-PLEX100...

    TradingView•10/9/26•Bullish

    PYPD Valuation and Fair Value

    P/E
    -3.3x
    P/B
    20.6x
    See GNG's fair value

    PYPD Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -243.6%

    PYPD Competitors

    CompanyTicker
    The Joint CorpJYNT
    Coya Therapeutics, Inc. Common StockCOYA
    Humacyte IncHUMA
    ImmuCell CorporationICCC
    Corbus Pharmaceuticals HoldingCRBP
    Milestone Pharmaceuticals IncMIST
    Inovio Pharmaceuticals IncINO
    Rani Therapeutics Holdings IncRANI

    Sector: Healthcare

    PYPD Analyst Ratings

    Consensus
    Buy
    Analysts
    4
    Strong Buy
    1
    Buy
    3
    Hold
    0
    Sell
    0
    Strong Sell
    0

    PYPD Bull Case vs Bear Case

    Bear case

    • PYPD beat EPS estimates in 37.5% of its last 8 reported quarters.

    PYPD Earnings: Beat Rate and Next Report

    Beat rate
    3 of 8 quarters (37.5%)
    Average surprise
    -6.3%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $0.27
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 0 down

    Frequently Asked Questions About PYPD

    Does PYPD pay dividends?

    PolyPid (PYPD) does not currently pay a regular dividend.

    What is PYPD's market cap?

    PolyPid (PYPD) has a market capitalization of $98.11M with a current stock price of $4.90.

    Related stocks

    Sector: Healthcare

    All stocks starting with P

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In